Glaxo Group Ltd. v. Apotex, Inc. — ANDA Filing Alone Cannot Support a Willful Infringement Finding Under Hatch-Waxman
The Federal Circuit established that a generic drug company’s filing of an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification cannot, by itself, constitute willful patent infringement or justify enhanced damages and attorney fees.